PKC-EPSILON INHIBITORS
    1.
    发明申请
    PKC-EPSILON INHIBITORS 有权
    PKC-EPSILON抑制剂

    公开(公告)号:US20150005349A1

    公开(公告)日:2015-01-01

    申请号:US14321727

    申请日:2014-07-01

    摘要: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

    摘要翻译: 本发明涉及新的AGC激酶抑制剂,特别是涉及式I或II的化合物或其立体异构体,互变异构体,外消旋,代谢物,前体或前药,盐,水合物或溶剂合物,其中Ar,Cy,R 1 ,R3,p和n具有权利要求中限定的含义。 特别地,本发明更具体地涉及AGC激酶抑制剂,包含这种抑制剂的组合物,特别是药物,以及这些抑制剂在治疗和预防疾病中的用途。

    PKC-epsilon inhibitors
    2.
    发明授权
    PKC-epsilon inhibitors 有权
    PKC-ε抑制剂

    公开(公告)号:US08785648B1

    公开(公告)日:2014-07-22

    申请号:US13340406

    申请日:2011-12-29

    IPC分类号: A61K31/44 C07D213/72

    摘要: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I or II or a stereoisomer, tautomer, racemic, metabolite, pro- or pre-drug, salt, hydrate, or solvate thereof, wherein Ar, Cy, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

    摘要翻译: 本发明涉及新的AGC激酶抑制剂,特别是涉及式I或II的化合物或其立体异构体,互变异构体,外消旋,代谢物,前体或前药,盐,水合物或溶剂合物,其中Ar,Cy,R 1 ,R3,p和n具有权利要求中限定的含义。 特别地,本发明更具体地涉及AGC激酶抑制剂,组合物,特别是包含这种抑制剂的药物,以及这些抑制剂在治疗和预防疾病中的用途。

    Hydroxyalkanoyl aminopyrazoles and related compounds
    8.
    发明授权
    Hydroxyalkanoyl aminopyrazoles and related compounds 失效
    羟基烷酰基氨基吡唑及其相关化合物

    公开(公告)号:US07053220B2

    公开(公告)日:2006-05-30

    申请号:US10355700

    申请日:2003-01-31

    IPC分类号: C07D285/135

    CPC分类号: C07D233/80 C07D233/74

    摘要: This invention is directed to a class of compounds (Formula I) including hydroxyalkanoyl amino pyrazoles, hydroxyalkanoyl amino thiadiazoles, hydroxyalkanoyl amino acid esters, hydroxyalkanoyl amino acid amides, hydroxyalkanoyl amino alcohols, hydroxyalkanoyl amino ketoes, hydroxyalkanoyl amino hydantoins, hydroxyalkanoyl anilines, and hydroxyalkanoyl derivatives of privileged structures. The invention is also directed to a pharmaceutical formation comprising such compound in a pharmaceutically acceptable salt form or prodrug thereof. The invention is further directed to a method for inhibiting β-amyloid peptide release and/or synthesis, a method for inhibiting γ-secretase activity and a method for treating neurological disorders associated with β-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention and treatment of Alzheimer's disease.

    摘要翻译: 本发明涉及一类包括羟基烷酰基氨基吡唑,羟基烷酰基氨基噻二唑,羟基烷酰基氨基酸酯,羟基烷酰基氨基酸酰胺,羟基烷酰基氨基醇,羟基链烷酰基氨基酮,羟基链烷酰基氨基乙内酰脲,羟基烷酰基苯胺和羟基烷酰基衍生物 的特权结构。 本发明还涉及药物组合物,其包含药学上可接受的盐形式的这种化合物或其前体药物。 本发明进一步涉及一种抑制β-淀粉样蛋白肽释放和/或合成的方法,一种抑制γ-分泌酶活性的方法和一种治疗与β-淀粉样蛋白肽生产相关的神经障碍的方法。 该方法包括向宿主施用包含有效量的式I化合物的药物制剂。式I化合物可用于预防和治疗阿尔茨海默氏病。